In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about how the recent NASDAQ ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

How one Big Pharma ad campaign is incorporating diversity as a driving force in improving the ways drugs are marketed ...

James Foster, CEO and co-founder of Virax Biolabs, discusses how AI and machine-learning algorithms are changing the ways that companies approach their launch strategies.

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about the challenges faced in developing T cell engagers.

Click the title above for a link to open the Pharmaceutical Executive February 2025 issue in an interactive PDF format.

James Foster, CEO and co-founder of Virax Biolabs, discusses how companies can strategize despite hard-to-predict regulatory headwinds.

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...